PPD Enhances Central Lab Data Capabilities for Sites
PPD has expanded Preclarus, its clinical data platform, to enable study sites to access central lab data in real time, and improve inventory management and order tracking, among other features.
PPD has expanded Preclarus, its clinical data platform, to include a comprehensive set of data solutions that supports the company’s central lab operations. These changes will enable study sites to access central lab data in real time, improve inventory management and order tracking, facilitate patient management and safety, and establish complete chain of custody for samples. The goal of these enhancements is to increase the efficiency and effectiveness of managing central lab data for PPD’s clients.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
